17.00USD-0.85%Mkt Cap: 801.96M USDP/E: —Last update: 2026-06-01
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-inte…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap801.96M USD
Enterprise Value704.77M USD
Revenue (TTM)2.98M USD
Gross Profit-118.20M USD
Net Income (TTM)-148.65M USD
Revenue/Share0.1030 USD
Last Price17.00 USD
Fiscal Year EndDec 2025
MR QuarterDec 2023
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.67
EV/Revenue236.82
P/S269.63
P/B-0.76
EPS (TTM)-5.39
EPS (Forward)—
52W Range
15.3533% of range20.30
52W High20.30 USD
52W Low15.35 USD
Profitability
Gross Margin0.00%
Oper. Margin-10739.72%
EBITDA Margin0.00%
Profit Margin-4994.86%
ROE30.44%
ROA-55.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.47M USD
CapEx (TTM)1.23M USD
FCF Margin-2857.83%
FCF Yield-10.61%
Net Debt-152.62M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity-0.06
Current Ratio7.20
Quick Ratio6.85
Book Value/Sh-22.4990 USD
Cash/Share8.617 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.47.17M
Float11.59M
Insiders1.97%
Institutions38.40%
Short Interest
Short Ratio0.1d
Short % Float0.21%
Short % Out.0.18%
Shares Short86.50K
Technical
SMA 5017.42 (-2.4%)
SMA 20017.42 (-2.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)469.12K
Avg Vol (10d)374.52K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—